2 Observations on Hopkinton Drug FDA-483

FDA has released an FDA-483 with two observations issued following an 8/25-11/2/20 inspection at Hopkinton Drug, a Hopkinton, MA, producer of non-sterile drug products. The two observations were: 

  • non-microbial contamination observed in the production area; and
  • failing to provide adequate segregation, cleaning of work surfaces, and cleaning of utensils to prevent cross-contamination when producing hazardous drugs.

Read more